Orano Appoints Frédéric Desdouits As Chief Executive Officer Of Orano Med

He is expected to advance the development of a diversified pipeline of lead-212–based targeted alpha therapies, from early discovery through clinical development, both internally and in partnership with collaborators.

Orano Med’s current pipeline includes one advanced clinical program and three Phase 1 clinical trials. The company is also expanding its industrial platform to enable commercial-scale production of lead-212–based targeted alpha therapies.

Prior to joining the group, Frédéric Desdouits served as CEO of TreeFrog Therapeutics, a French biotech company focused on stem cell–based therapies. He also led the pharmaceutical activities at Seqens and oversaw business development and U.S. pharmaceutical operations at Pierre Fabre.

Frederic Desdouits commented: “I am pleased to join the Orano Med team at a pivotal moment in its development. The biotech company has unique scientific and industrial assets to accelerate innovation in the field of radioligand therapy. As the clinical development of AlphaMedix, the most advanced drug candidate, continues in partnership with Sanofi, our clinical pipeline has significantly expanded in recent months and now includes three lead-212-based drug candidates.

In parallel, additional R&D projects are underway to identify and progress new molecules towards the clinic. Our dynamic development positions us among the global leaders in the emerging field of targeted alpha therapy. Together with the entire team, I am fully committed to turning this potential into tangible benefits for patients.”

Read Also - Bristol’s Narwhal Labs Raises €22.9M Funding And Launches DeepBlue OS

Earlier in his career, he co-founded Bionest Partners, a healthcare-focused strategy and financial consulting firm, and led the European pharmaceutical and biotech research team at Exane BNP Paribas. He began his career in pharmaceutical research.

Since 2022, Desdouits has been a member of the Orano Med Governing Board and also serves as Vice President of the industry association France Biotech.

He graduated from École Polytechnique, holds a PhD in neurosciences from the University of Paris VI Sorbonne, and completed postdoctoral research at Rockefeller University in New York.

Orano Med is a clinical-stage biotech subsidiary of Orano developing targeted cancer therapies using lead-212 (212Pb), an alpha-emitting radioisotope used in Targeted Alpha Therapy.

The company advances radioligand treatments and is expanding GMP manufacturing across France, the US, North America, and Europe.

Nicolas Maes, Chief Executive Officer of the Orano group, declared: “The extensive experience of Frederic Desdouits in the pharmaceutical industry, particularly in the biotechnology sector, will be a valuable asset in accelerating the development of the clinical portfolio as well as the deployment of Orano Med’s industrial platform. As a member of the Governance Board since 2022, he already has a deep understanding of Orano Med’s activities and challenges, which will facilitate his swift involvement in strategic decision-making.”